• Clinical Insights: May 26, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kevzara® (sarilumab) – May 22, 2017 – Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the January 2017 edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Spinraza™ (nusinersen) – December 23, 2016 – The U.S. Food & Drug Administration (FDA) approved Spinraza™ (nusinersen), the first drug approved to treat children and adults with… Read more »

  • Clinical Insights — September 2016 Issue

    Welcome to the September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Amjevita™ (adalimumab-atto) – September 23, 2016 – The U.S. Food and Drug Administration (FDA) approved Amjevita™ (adalimumab-atto) as a biosimilar to Humira® (adalimumab) for multiple inflammatory diseases. Read More.… Read more »

  • Clinical Insights — August 2016 Issue

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Adlyxin™ (lixisenatide) – July 28, 2016 – The U.S. Food and Drug Administration approved Adlyxin™ (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with… Read more »

  • Clinical Insights — April 2016 Issue

    Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Venclexta™ (venetoclax) April 11, 2016 – The U.S. Food and Drug Administration approved Venclexta™ (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who… Read more »

  • Clinical Insights — March 2016 Issue

    Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Briviact® (brivaracetam)  February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset… Read more »

  • Clinical Insights — January Issue 2

    Welcome to the second January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Formulation Approval Humulin® R KwikPen® (insulin human injection) – New Formulation Approval January 21, 2016 – The U.S. Food and Drug Administration approved Eli Lilly and Company’s Humulin®… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the first January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Zurampic® (lesinurad) December 22, 2015 – The U.S. Food and Drug Administration approved Zurampic® (lesinurad) to treat high levels of uric acid in the blood… Read more »

  • RxStrategies Clinical Insights — November 2015, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Ninlaro® (ixazomib) November 20, 2015 – The U.S. Food and Drug Administration approved ixazomib (Ninlaro®, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical… Read more »

  • RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »